{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:59:23Z","timestamp":1759838363357},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>We assessed immunogenicity, antibody persistence and safety of the meningococcal serogroups A, C, W and Y-tetanus toxoid (TT) conjugate vaccine (MenACWY-TT) in children primed as toddlers with MenC vaccine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This open, multicenter extension study enrolled children 84\u201395 months of age who had received one dose of the combined <jats:italic toggle=\"yes\">Haemophilus influenzae<\/jats:italic> type b (Hib)-MenC-TT conjugate vaccine (HibMenC group) or Hib-TT and monovalent MenC (MCC)-CRM<jats:sub>197<\/jats:sub> vaccines (Hib+MCC group) at 12\u201318 months of age, in the primary study. All participants received one dose of MenACWY-TT. We assessed immunogenicity against MenA, MenC, MenW and MenY at 1 month and 2 years postvaccination by serum bactericidal assay using baby rabbit complement (rSBA). Safety and reactogenicity were evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Six years post-MenC vaccination, &lt;20% of children retained rSBA-MenC titers \u22651:8. At 1 month post-MenACWY-TT vaccination, vaccine response rates against all serogroups were high for both groups with \u226597.1% of children having rSBA \u22651:8. Two years postvaccination, \u226563.6% of children retained rSBA-MenA \u22651:8, and \u226587.9% for other serogroups. Geometric mean titers for all serogroups declined at 2 years post-MenACWY-TT vaccination, but remained \u226513 times higher than prevaccination levels. For both groups, pain (\u226458.5%), redness (\u226451.4%) and fatigue (\u226427.0%) were the most frequently reported adverse events. No serious adverse events were reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>One dose of MenACWY-TT boosts protection against MenC in primed children, is safe and extends protection against MenA, MenW and MenY. Immunogenicity and safety were comparable in infants vaccinated with conjugated vaccine (HibMenC-TT) or the separate vaccines (Hib-TT and MCC-CRM<jats:sub>197<\/jats:sub>).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002334","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T04:18:46Z","timestamp":1558498726000},"page":"643-650","source":"Crossref","is-referenced-by-count":6,"title":["Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers"],"prefix":"10.1097","volume":"38","author":[{"given":"Terry","family":"Nolan","sequence":"first","affiliation":[{"name":"Vaccine and Immunisation Research Group, University of Melbourne School of Population and Global Health and Murdoch Children\u2019s Research Institute, Melbourne, Victoria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Booy","sequence":"additional","affiliation":[{"name":"National Centre for Immunisation Research and Surveillance (NCIRS), The Children\u2019s Hospital at Westmead, University of Sydney, Sydney, New South Wales"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen S.","family":"Marshall","sequence":"additional","affiliation":[{"name":"Adelaide Medical School and Robinson Research Institute, The University of Adelaide, Adelaide"},{"name":"Vaccinology and Immunology Research Trials Unit, Women\u2019s and Children\u2019s Health Network, Adelaide, South Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Richmond","sequence":"additional","affiliation":[{"name":"Division of Paediatrics, University of Western Australia School of Medicine, Perth, Western Australia"},{"name":"Vaccine Trials Group, Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Nissen","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital, University of Adelaide, Adelaide"},{"name":"Royal Children\u2019s Hospital, Brisbane, Queensland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B.","family":"Ziegler","sequence":"additional","affiliation":[{"name":"Sydney Children\u2019s Hospital, Randwick and School of Women\u2019s & Children\u2019s Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaela","family":"Baine","sequence":"additional","affiliation":[{"name":"GSK, King of Prussia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Traskine","sequence":"additional","affiliation":[{"name":"GSK, Wavre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Jastorff","sequence":"additional","affiliation":[{"name":"XPE Pharma & Science (C\/O GSK), Wavre, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Van der Wielen","sequence":"additional","affiliation":[{"name":"GSK, Wavre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"2 suppl","key":"R1-20230912","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines.","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"key":"R2-20230912","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis.","author":"Wang","year":"2019","journal-title":"Vaccine"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/322587","article-title":"Complications of meningococcal disease in college students.","volume":"33","author":"Erickson","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/adc.85.1.6","article-title":"Neurodevelopmental outcome in meningococcal disease: a case-control study.","volume":"85","author":"Fellick","year":"2001","journal-title":"Arch Dis Child"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"e979","DOI":"10.1542\/peds.2006-0281","article-title":"Multicenter surveillance of invasive meningococcal infections in children.","volume":"118","author":"Kaplan","year":"2006","journal-title":"Pediatrics"},{"issue":"suppl 2","key":"R6-20230912","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease.","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"R7-20230912","first-page":"E121","article-title":"Meningococcal disease in childhood: epidemiology, clinical features and prevention.","volume":"56","author":"Bosis","year":"2015","journal-title":"J Prev Med Hyg"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1473-3099(17)30301-8","article-title":"Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data.","volume":"17","author":"Trotter","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1080\/21645515.2015.1051276","article-title":"Meningococcal serogroup Y disease in Europe: continuation of high importance in some European regions in 2013.","volume":"11","author":"Br\u00f6ker","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/cid\/ciu881","article-title":"Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales.","volume":"60","author":"Ladhani","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1017\/S0950268816000704","article-title":"Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme.","volume":"144","author":"Lawrence","year":"2016","journal-title":"Epidemiol Infect"},{"key":"R12-20230912","first-page":"E454","article-title":"Rise in invasive serogroup W meningococcal disease in Australia 2013-2015.","volume":"40","author":"Martin","year":"2016","journal-title":"Commun Dis Intell Q Rep"},{"issue":"suppl 2","key":"R13-20230912","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1016\/j.vaccine.2009.04.067","article-title":"Meningococcal C conjugate vaccine: the experience in England and Wales.","volume":"27","author":"Campbell","year":"2009","journal-title":"Vaccine"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.vaccine.2014.03.010","article-title":"Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.","volume":"32","author":"Garrido-Estepa","year":"2014","journal-title":"Vaccine"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/INF.0b013e31820e8638","article-title":"Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.","volume":"30","author":"De Wals","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1017\/S0950268808001106","article-title":"Molecular surveillance of Neisseria meningitidis capsular switching in Portugal, 2002-2006.","volume":"137","author":"Sim\u00f5es","year":"2009","journal-title":"Epidemiol Infect"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"e12144","DOI":"10.1371\/journal.pone.0012144","article-title":"Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine.","volume":"5","author":"de Voer","year":"2010","journal-title":"PLoS One"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.vaccine.2009.01.026","article-title":"Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006.","volume":"27","author":"Kinlin","year":"2009","journal-title":"Vaccine"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"e0139615","DOI":"10.1371\/journal.pone.0139615","article-title":"Changes in meningococcal strains in the era of a serogroup C vaccination campaign: trends and evolution in Belgium during the period 1997-2012.","volume":"10","author":"Mattheus","year":"2015","journal-title":"PLoS One"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jinf.2012.09.008","article-title":"Epidemiology of invasive meningococcal disease in Germany, 2002-2010, and impact of vaccination with meningococcal C conjugate vaccine.","volume":"66","author":"Hellenbrand","year":"2013","journal-title":"J Infect"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2334-12-35","article-title":"Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.","volume":"12","author":"Kaaijk","year":"2012","journal-title":"BMC Infect Dis"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/INF.0b013e31820a8b3c","article-title":"Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine.","volume":"30","author":"Macneil","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1128\/CVI.05354-11","article-title":"Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.","volume":"18","author":"Khatami","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1574-6976.2006.00053.x","article-title":"Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7748\/ncyp2013.11.25.9.16.e466","article-title":"Immunisation: changes in the UK for children and young people.","volume":"25","author":"Donovan","year":"2013","journal-title":"Nurs Child Young People"},{"issue":"No. RR-2","key":"R27-20230912","first-page":"1","article-title":"Prevention and control of meningococcal disease recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","year":"2013","journal-title":"Morb Mortal Wkly Rep"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1136\/bmj.39563.545255.AE","article-title":"Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.","volume":"336","author":"Snape","year":"2008","journal-title":"BMJ"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"e23497","DOI":"10.1371\/journal.pone.0023497","article-title":"Age-related immunity to meningococcal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in the avidity of IgG.","volume":"6","author":"de Voer","year":"2011","journal-title":"PLoS One"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/archdischild-2013-303893","article-title":"Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.","volume":"98","author":"de Whalley","year":"2013","journal-title":"Arch Dis Child"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1097\/INF.0000000000000898","article-title":"Five-year antibody persistence and safety after a single dose of combined Haemophilus influenzae type b Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Haemophilus influenzae type b-primed toddlers.","volume":"34","author":"Booy","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","article-title":"Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.","volume":"24","author":"Snape","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/CVI.00384-09","article-title":"Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine.","volume":"17","author":"Borrow","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1128\/CVI.05655-11","article-title":"Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction.","volume":"19","author":"Ishola","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"R35-20230912","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/INF.0b013e31820013d2","article-title":"Immediate and longer term immunogenicity of a single dose of the combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age.","volume":"30","author":"Booy","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R36-20230912","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"R37-20230912","first-page":"780","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England.","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"R38-20230912","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R39-20230912","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"key":"R40-20230912","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity.","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"R41-20230912","first-page":"1016","article-title":"Inadvertent misadministration of meningococcal conjugate vaccine-United States, June-August 2005.","volume":"55","year":"2006","journal-title":"Morb Mortal Wkly Rep"},{"key":"R42-20230912","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1097\/INF.0000000000000897","article-title":"Immunogenicity, safety and antibody persistence of a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine compared with monovalent meningococcal serogroup C vaccine administered four years after primary vaccination using the same vaccines.","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R43-20230912","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/INF.0000000000001123","article-title":"Five-year antibody persistence and booster response after 1 or 2 doses of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in healthy children.","volume":"35","author":"Klein","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R44-20230912","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/652765","article-title":"Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.","volume":"50","author":"Perrett","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R45-20230912","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2018.04.064","article-title":"Antibody persistence and booster response 68 months after vaccination at 2-10 years of age with one dose of MenACWY-TT conjugate vaccine.","volume":"36","author":"Knuf","year":"2018","journal-title":"Vaccine"},{"key":"R46-20230912","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/21645515.2015.1058457","article-title":"Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine.","volume":"12","author":"Vesikari","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"R47-20230912","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1128\/CVI.00279-08","article-title":"Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.","volume":"15","author":"Trotter","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"R48-20230912","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1097\/INF.0000000000001861","article-title":"Evidence for rise in meningococcal serogroup C bactericidal antibody titers in the absence of booster vaccination in previously vaccinated children.","volume":"37","author":"Badahdah","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"R49-20230912","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00431-012-1924-0","article-title":"Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.","volume":"172","author":"Knuf","year":"2013","journal-title":"Eur J Pediatr"},{"key":"R50-20230912","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/INF.0b013e31820e6e02","article-title":"Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile.","volume":"30","author":"Memish","year":"2011","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201906000-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:29:28Z","timestamp":1694557768000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201906000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002334","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}